Cutaquig SCIg | Safety and Manufacturing

Cutaquig manufacturing and purification process1-3


Pathogen safety explanation chart

Cutaquig contains all 4 subclasses of IgG, with a percentage distribution equivalent to the one found in normal plasma.

  • Cutaquig is made from large pools of donated plasma which go through a rigorous purification process for the inactivation and removal of viruses
  • Other precautions against viral transmission include: selection of plasma donors, screening of donations and plasma pool, as well as final product testing for viruses
  • Cutaquig is manufactured by the cold ethanol fractionation process followed by ultrafiltration and chromatography. The manufacturing process includes treatment with a Solvent/Detergent (S/D), and incubation at low pH.

Viral removal and inactivation1

Cutaquig manufacturing process shows significant viral reduction within in vitro studies.

Production Step In vitro reduction factor [log10]
Enveloped Viruses Non-Enveloped Viruses
HIV-1 PRV SBV MEV PPV
Cold ethanol fractionation ≥ 4.81 ≥ 6.28 ≥ 7.13 ≥ 7.13 ≥ 6.53
S/D treatment ≥ 4.93 5.23 ≥ 6.77 n.a. n.a.
pH 4 treatment ≥ 4.33 ≥ 6.71 6.71 5.07 < 1*
Global reduction factor ≥ 14.07 ≥ 18.22 ≥ 20.61 ≥ 12.20 ≥ 6.53

*Not calculated for global LRF.
HIV-1: Human Immunodeficiency Virus – 1; PRV: Pseudorabies Virus, model virus for e.g. Hepatitis B Virus (HBV); SBV: Sindbis Virus model virus for Hepatitis C Virus (HCV); MEV: Mouse Encephalomyelitis Virus, model virus for Human Parvovirus B19; PPV: Porcine Parvovirus, model virus for Hepatitis A Virus (HAV).

Review the clinical efficacy and safety of cutaquig here.

Learn More

References:
  1. Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.
  2. Octapharma, Data on File.
  3. Buchacher A, Kaar W. Intravenous immunoglobulin G from human plasma– purification concepts and important quality criteria. In: Bertolini J, Goss N, Curling J, eds. Production of Plasma Proteins for Therapeutic Use. Hoboken, NJ: John Wiley & Sons, Inc; 2013.